Status: Recruiting
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Cohort 1 \[CLOSED\] Study treatment involves two segments: (1) Induction Immunotherapy segment with pembrolizumab monotherapy every 3 weeks until irRECIST PD and (2) Combination Therapy segment. Nab-paclitaxel may be utilized in place of paclitaxel at investigator's discretion for subjects with paclitaxel reactions. Cohort 2 Patients are randomized to Arm A or B. Treatment in both arms includes pembrolizumab + RAM + paclitaxel.
Participants needed: 58
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Harry H YoonUpdated: Jul 31, 2025Locations: 2
Eligibility criteria
Written informed consent and HIPAA authorization for release of personal health... [+22]
Past medical history of interstitial lung disease (ILD), drug-induced ILD, radia... [+42]